Sharechat Logo

HGH - Amended Notification of Allotment of Securities

Friday 22nd September 2023

Text too small?

Amended Capital Change Notice to reflect the correct total number of Financial Products of the Class after the issue/acquisition/redemption/Conversion (excluding Treasury Stock) being 715,265,270 ordinary shares (excluding Treasury Stock).

 

Section 1: Issuer information

Name of issuer: Heartland Group Holdings Limited

NZX ticker code: HGH

Class of financial product: Ordinary shares

ISIN (If unknown, check on NZX website): NZHGHE0007S9

Currency: NZD

 

Section 2: Capital change details

Number issued/acquired/redeemed: 4,790,946

Nominal value (if any): N/A

Issue/acquisition/redemption price per security: $1.68653026

Nature of the payment (for example, cash or other consideration): Consideration satisfied pursuant to the Dividend Reinvestment Plan

Amount paid up (if not in full): Fully paid ordinary shares

Percentage of total class of Financial Products issued/acquired/redeemed/ (calculated on the number of Financial Products of the Class, excluding any Treasury Stock, in existence): 0.67% of the total number of fully paid ordinary shares prior to this issue

For an issue of Convertible Financial Products or Options, the principal terms of Conversion (for example the Conversion price and Conversion date and the ranking of the Financial Product in relation to other Classes of Financial Product) or the Option (for example, the exercise price and exercise date): N/A

Reason for issue/acquisition/redemption and specific authority for issue/acquisition/redemption/ (the reason for change must be identified here): Issue of ordinary shares to those shareholders that have elected to participate in the HGH Dividend Reinvestment Plan, approved by directors’ resolutions.

Total number of Financial Products of the Class after the issue/acquisition/redemption/Conversion (excluding Treasury Stock) and the total number of Financial Products of the Class held as Treasury Stock after the issue/acquisition/redemption: 715,265,270 ordinary shares (excluding Treasury Stock); 459,070 Treasury Stock

In the case of an acquisition of shares, whether those shares are to be held as treasury stock:N/A

Specific authority for the issue, acquisition, or redemption, including a reference to the rule pursuant to which the issue, acquisition, or redemption is made:Directors’ resolution

Issue of Ordinary Shares under Listing Rule 4.8.1

Terms or details of the issue, acquisition, or redemption (for example: restrictions, escrow arrangements): Pursuant to the terms of the HGH Dividend Reinvestment Plan Offer Document dated 10 December 2018

Date of issue/acquisition/redemption: 20 September 2023

 

Section 3: Authority for this announcement and contact person

Name of person authorised to make this announcement: Andrew Dixson, Chief Financial Officer

Contact person for this announcement: Nicola Foley, Group Head of Communications

Contact phone number: 027 345 6809

Contact email address: Nicola.Foley@heartland.co.nz

Date of release through MAP: 22/09/2023



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

WCO - Acquisition of Civic Waste, Convertible Note & SPP
ATM - FY25 revenue guidance and dividend policy
November 22th Morning Report
General Capital Announces Another Profit Record
Infratil Considers Infrastructure Bond Offer
Argosy FY25 Interim Result
Meridian Energy monthly operating report for October 2024
Du Val failure offers fresh lessons, but will they be heeded in the long term?
November 19th Morning Report
ATM - Appointment of new independent NED